17 Oct, 2021 Patent term extensions in Australia – What if the patent covers more than one approved product? By Nicholas Tyacke Alexandra de Zwart In its second significant recent decision addressing patent term extensions in Australia, the Federal Court of Australia, in Merck Sharp...
08 Oct, 2021 Key takeaways from the ABPI Clinical Research Report 2021 By Richard Taylor Elinor Cavil The ABPI (Association of British Pharmaceutical Industries, the UK trade association for producers of prescription medicines) launched...
07 Oct, 2021 Understanding AI and its use in drug discovery By Ellen Scordino Susan Krumplitsch As part of our on-going podcast series - At the intersection of Science and Law, DLA Piper partners Ellen Scordino and Susan Krumplitsch...
07 Oct, 2021 New Clinical Trial Rules in the EU: A Practical Overview of the Upcoming Regulation By Marco de Morpurgo Carlotta Busani With the upcoming application of the new EU Clinical Trials Regulation (‘CTR’), the conduct of clinical trials in the European Union...
06 Oct, 2021 TGA to permit COVID-19 rapid antigen self-tests in Australia from November 2021 By Greg Bodulovic Alexandra Moore Matt Rozario The Australian Therapeutic Goods Administration (TGA) has introduced changes to permit the use of COVID-19 rapid antigen self-testing and...
05 Oct, 2021 Update: DLA Piper Global COVID-19 Vaccine Guide for Employers By Marco de Morpurgo DLA Piper’s Life Sciences team has updated our recent vaccine guide for employers. The changes include the additions of Sweden and...
04 Oct, 2021 Update: Poland - Plan for Rare Diseases for 2021-2023 By Amelia Prawda In the last week of September 2021, the Polish Cabinet finally published the Plan for Rare Diseases for 2021-2023 (the "Plan"). We...